Ginkgo Bioworks
DNA
125 hedge funds and large institutions have $9.18B invested in Ginkgo Bioworks in 2021 Q3 according to their latest regulatory filings, with 125 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
101% more call options, than puts
Call options by funds: $40.1M | Put options by funds: $20M
1.49% more ownership
Funds ownership: 0% → 1.49% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$4.13B |
| 2 |
GA
General Atlantic
New York
|
+$1.4B |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$1.11B |
| 4 |
SIG
Senator Investment Group
New York
|
+$958M |
| 5 |
ACG
Anchorage Capital Group
New York
|
+$817M |
Top Sellers
DNA Hedge Fund Activity: Q3 2021 in Review
125 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q3 2021, worth a combined $9.18B.
Buyers outnumbered sellers: 125 funds opened new DNA positions and 0 closed out — a net gain of 125 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $4.13B.
- 125 institutional investors held Ginkgo Bioworks (DNA) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $9.18B of Ginkgo Bioworks stock for Q3 2021.
- 125 funds opened new Ginkgo Bioworks positions in Q3 2021 and 0 closed out, a net change of +125 holders.
- The largest Ginkgo Bioworks buyer in Q3 2021 was Viking Global Investors, an estimated $4.13B added.
Based on aggregated 13F filings for Q3 2021.